In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.

Below is Validea's guru fundamental report for VERTEX INC (VERX). Of the 22 guru strategies we follow, VERX rates highest using our P/B Growth Investor model based on the published strategy of ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Shares of NASDAQ:VERX opened at $35.55 on Wednesday. Vertex has a 1-year low of $27.22 and a 1-year high of $60.71. The firm has a market capitalization of $5.62 billion, a PE ratio of 197.50, a ...

Zurich-based start-up Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies ...

Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger ...